Table 5 Cost-utility results of SL versus IV edaravone
Groups | Costs | QALYs | Incremental cost | Incremental QALYs | ICER (￥/QALY) |
|---|---|---|---|---|---|
SL | ￥92,864.81 | 1.629 | ￥12,670.04 | 0.034 | 372,648.24 |
IV | ￥80,194.77 | 1.595 |
Groups | Costs | QALYs | Incremental cost | Incremental QALYs | ICER (￥/QALY) |
|---|---|---|---|---|---|
SL | ￥92,864.81 | 1.629 | ￥12,670.04 | 0.034 | 372,648.24 |
IV | ￥80,194.77 | 1.595 |
Orphanet Journal of Rare Diseases